<!DOCTYPE html>
<html lang="en-US"><head>
		<meta charset="UTF-8">
		<title>FR940803-0-00042</title>
	</head>
	<body>
		<main>
			<p><!-- PJG ITAG l=10 g=1 f=2 --> EFFECTIVE DATE:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 --> August 3, 1994. <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->   <!-- PJG 0012 frnewline --> <!-- PJG STAG 4700 -->  <!-- PJG ITAG l=94 g=1 f=2 -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=69 g=1 f=2 -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=50 g=1 f=2 -->   <USDEPT>DEPARTMENT OF HEALTH AND HUMAN SERVICES</USDEPT>  <!-- PJG /ITAG -->  <!-- PJG ITAG l=18 g=1 f=2 -->  <USBUREAU>Food and Drug Administration</USBUREAU> <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=52 g=1 f=2 -->  <CFRNO>21 CFR Part 520 </CFRNO> <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=55 g=1 f=2 --> Oral Dosage Form New Animal Drugs; Chlortetracycline Soluble Powder  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <AGENCY> <!-- PJG ITAG l=10 g=1 f=2 --> AGENCY: <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 -->  Food and Drug Administration, HHS. <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->   <!-- PJG 0012 frnewline --> </AGENCY> <ACTION> <!-- PJG ITAG l=10 g=1 f=2 --> ACTION: <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 -->  Final rule.  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=59 g=1 f=1 -->   <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </ACTION> <SUMMARY> <!-- PJG ITAG l=10 g=1 f=2 --> SUMMARY: <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 -->  The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect approval of two supplemental new animal drug applications (NADA's) filed by the American Cyanamid Co. The supplemental NADA's provide for the safe and effective use of chlortetracycline hydrochloride (CTC HCl) soluble powder in both the drinking water of chickens and turkeys for control of certain bacterial diseases susceptible to CTC, and the drinking water of swine and cattle for control and treatment of certain bacterial diseases susceptible to CTC. The approvals reflect compliance with results of the National Academy of Sciences/National Research Council (NAS/NRC), Drug Efficacy Study Group's (DESI) evaluation of the drugs' effectiveness and FDA's conclusions concerning that evaluation. <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->   <!-- PJG 0012 frnewline --> </SUMMARY> <DATE> <!-- PJG ITAG l=10 g=1 f=2 --> EFFECTIVE DATE:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 --> August 3, 1994. <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->   <!-- PJG 0012 frnewline --> </DATE> <FURTHER> <!-- PJG ITAG l=10 g=1 f=2 --> FOR FURTHER INFORMATION CONTACT: <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 -->  Dianne T. McRae, Center for Veterinary Medicine (HFV&hyph;102), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301&hyph;594&hyph;1623. <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->   <!-- PJG 0012 frnewline --> </FURTHER> <SUPPLEM> <!-- PJG ITAG l=10 g=1 f=2 --> SUPPLEMENTARY INFORMATION: <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 -->  American Cyanamid Co., Berdan Ave., Wayne, NJ 07470, submitted a supplement to its approved NADA 65&hyph;071 for Aureomycin <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=6 f=2 --> &reg; <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 -->  (chlortetracycline hydrochloride (CTC HCl)) Soluble Powder (available in 181 gram (g) (6.4 ounce (oz) packets and 2.3 kilogram (kg) (5 pound (lb) bags, with a concentration of 25 g CTC HCl/lb) and NADA 65&hyph;440 for Aureomycin <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=6 f=2 --> &reg; <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 -->  (CTC HCl) Soluble Powder Concentrate (available in 181 g (6.4 oz) and 726 g (25.6 oz) packets, with a concentration of 64 g CTC HCl/lb). The drug products are used to medicate drinking water to be administered to chickens, turkeys, swine, calves, beef cattle, and nonlactating dairy cattle in accordance with &sect;520.445b(d)(4) (21 CFR 520.445b(d)(4)). Both NADA's were originally approved on June 23, 1953, as antibiotic Form 6 applications.  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> The drugs were the subject of a NAS/NRC DESI evaluation of effectiveness (DESI 0113NV). The findings were published in the  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=4 --> Federal Register <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  of July 21, 1970 (35 FR 11646). NAS/NRC evaluated the drugs as probably effective for growth promotion and feed efficiency and for the treatment of animal diseases caused by pathogens sensitive to chlortetracycline. NAS/NRC stated:  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=21 g=1 f=1 --> (1) Claims made regarding ``for prevention of'' or ``to prevent'' should be replaced with ``as an aid in the control of'' or ``to aid in the control of'';  <!-- PJG 0012 frnewline --> (2) claims for growth promotion or stimulation are disallowed and claims for faster gains and/or feed efficiency should be stated as ``may result in faster gains and/or improved feed efficiency under appropriate conditions'';  <!-- PJG 0012 frnewline --> (3) each disease claim should be properly qualified as ``appropriate for use in (name of disease) caused by pathogens sensitive to (name of drug)''; if the disease cannot be so qualified the claim must be dropped;  <!-- PJG 0012 frnewline --> (4) claims pertaining to egg production and hatchability should be changed to ``May aid maintaining egg production and hatchability, under appropriate conditions, by controlling pathogenic microorganisms'';  <!-- PJG 0012 frnewline --> (5) the labels should warn that treated animals must actually be consuming enough medicated water or medicated feed to provide a therapeutic dosage under the conditions that prevail and, as a precaution, state the desired oral dose per unit of animal weight per day for each species as a guide to effective usage of the preparation in drinking water or feed; and  <!-- PJG 0012 frnewline --> (6) effective blood levels are required for each recommended dosage.  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> FDA concurred with the NAS/NRC findings.  <!-- PJG 0012 frnewline --> The NAS/NRC evaluation is concerned only with the drugs' effectiveness and safety to the treated animal. It does not take into account the safety for food use of food derived from drug-treated animals. Nothing herein will constitute a bar to further proceedings with respect to questions of safety of the drugs or their metabolites in food products derived from treated animals.  <!-- PJG 0012 frnewline --> The American Cyanamid Co. filed supplemental NADA's which revised the labeling of its products to comply with the results of the NAS/NRC DESI review and FDA's conclusions. The supplemental NADA's are approved as of June 15, 1994, and the regulations are amended by revising &sect;520.445b (21 CFR 520.445b) to reflect the approvals.  <!-- PJG 0012 frnewline --> Additionally, &sect;520.445b(b) is amended to reflect sponsor approvals as a result of this latest DESI finalization:  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=21 g=1 f=1 --> 1. Drug sponsor no. 053389 (Pennfield Oil Co.) is currently codified for the uses provided in &sect;520.445b(d)(3) and (d)(4). Actually, the approval is limited to the uses provided only in &sect;520.445b(d)(2)(i)(D) and (d)(3)(i)(A).  <!-- PJG 0012 frnewline --> 2. Drug sponsor no. 010042 (American Cyanamid Co.) is currently codified for the uses provided in &sect;520.445b(d)(1) and (d)(2). However, approval of its applications is now limited to the uses listed in &sect;520.445b(d)(4).  <!-- PJG 0012 frnewline --> 3. Drug sponsor no. 054273 (Fermenta Animal Health Co.) is codified for all of the current uses in &sect;520.445b(d)(4), which is being amended because the sponsor does not hold an approval for the claim added in paragraph (d)(4)(i)(C) of &sect;520.445b.  <!-- PJG 0012 frnewline --> 4. Drug sponsor no. 017274 (Feed Specialties Co., Inc.) is currently codified for the uses provided in &sect;520.445b(d)(4)(i) through (d)(4)(iii). However, this is being amended because the sponsor does not hold an approval for the claim added in paragraph (d)(4)(i)(C).  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> As a result of the DESI finalization, &sect;520.445b(d)(1) and (d)(2) are being removed (for claims no longer acceptable) and new paragraph (d)(4)(i)(C) is being added to reflect a claim for control of mortality due to fowl cholera caused by  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Pasteurella multocida <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> .  <!-- PJG 0012 frnewline --> Section 520.445b is further amended in paragraphs (d)(4)(iii)(B) and (d)(4)(iv)(B) to change the name of one of the causative agents,  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Hemophilus <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> , to  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Actinobacillus pleuropneumoniae <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> , the current scientific name.  <!-- PJG 0012 frnewline --> Finally, &sect;520.445b is amended in paragraph (d)(4)(iv)(C) to add warning statements now required on the labeling.  <!-- PJG 0012 frnewline --> The agency has carefully considered the potential environmental effects of this action. FDA has concluded that the action will not have a significant impact on the human environment, and that an environmental impact statement is not required. The agency's finding of no significant impact and the evidence supporting that finding, contained in an environmental assessment, may be seen in the Dockets Management Branch (HFA&hyph;305), Food and Drug Administration, rm. 1&hyph;23, 12420 Parklawn Dr., Rockville, MD 20857, between 9 a.m. and 4 p.m., Monday through Friday.  <!-- PJG 0012 frnewline --> Under section 512(c)(2)(F)(iii) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360b(c)(2)(F)(iii)), these approvals for food producing animals do not qualify for marketing exclusivity because the supplemental applications do not contain reports of new clinical or field investigations (other than bioequivalence or residue studies) and new human food safety studies (other than bioequivalence or residue studies) essential to the approvals and conducted or sponsored by the applicant.  <!-- PJG 0012 frnewline --> In accordance with the freedom of information provisions of part 20 (21 CFR part 20) and &sect;514.11(e)(2)(ii) (21 CFR 514.11(e)(2)(ii)), a summary of safety and effectiveness data and information submitted to support approval of this application may be seen in the Dockets Management Branch (address above) between 9 a.m. and 4 p.m., Monday through Friday.  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=84 g=1 f=1 --> List of Subjects in 21 CFR Part 520  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> Animal drugs.  <!-- PJG 0012 frnewline --> Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs and redelegated to the Center for Veterinary Medicine, 21 CFR part 520 is amended as follows:  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=52 g=1 f=1 --> PART 520_ORAL DOSAGE FORM NEW ANIMAL DRUGS  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> 1. The authority citation for 21 CFR part 520 continues to read as follows: <!-- PJG /ITAG -->  <!-- PJG QTAG 04 --> <!-- PJG /QTAG -->   <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=21 g=1 f=1 -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=21 g=1 f=4 --> Authority: <!-- PJG /ITAG -->  <!-- PJG ITAG l=21 g=1 f=1 -->  Sec. 512 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360b). <!-- PJG /ITAG -->  <!-- PJG QTAG 04 --> <!-- PJG /QTAG -->   <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=21 g=1 f=1 --> 2. Section 520.445b is amended in paragraph (a) by adding ``, 64,'' after ``25.6'' and ``, 141,'' after ``56.4''; by revising paragraphs (b), (d)(1), (d)(2), (d)(4)(iii)(B), (d)(4)(iii)(C), (d)(4)(iv)(B), and (d)(4)(iv)(C); by removing and reserving paragraph (d)(3); and by adding new paragraph (d)(4)(i)(C) to read as follows:  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=80 g=1 f=1 --> &sect;520.445b  <!-- PJG /ITAG -->  <!-- PJG ITAG l=89 g=1 f=1 --> Chlortetracycline powder (chlortetracycline hydrochloride or chlortetracycline bisulfate).  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=37 g=1 f=1 --> * * * * *  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> (b)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Sponsors <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . See No. 053389 in &sect;510.600(c) of this chapter for conditions of use as in paragraphs (d)(1)(i)(A) and (d)(2)(i)(A) of this section; No. 010042 for conditions of use as in paragraph (d)(4) of this section; No. 054273 for conditions of use as in paragraphs (d)(4)(i)(A) and (B) and (d)(4)(ii) through (iv) of this section; No. 017274 for conditions of use as in paragraphs (d)(4)(i)(A) and (B) and (d)(4)(ii) and (iii) of this section.  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=37 g=1 f=1 --> * * * * *  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> (d)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Conditions of use <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . (1) Use as chlortetracycline hydrochloride in drinking water as follows:  <!-- PJG 0012 frnewline --> (i)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Swine <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . (A)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Amount <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . Ten milligrams per pound of body weight daily in divided doses.  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> (1) Indications for use <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . Control and treatment of bacterial enteritis (scours) caused by  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Escherichia coli <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  and bacterial pneumonia associated with  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Pasteurella <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  spp.,  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Actinobacillus pleuropneumoniae <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  ( <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Hemophilus <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  spp.), and  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Klebsiella <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  spp.  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> (2) Limitations <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . Prepare a fresh solution twice daily; as sole source of chlortetracycline; administer for not more than 5 days; do not slaughter animals for food within 5 days of treatment.  <!-- PJG 0012 frnewline --> (B) [Reserved]  <!-- PJG 0012 frnewline --> (ii) [Reserved]  <!-- PJG 0012 frnewline --> (2) Use as chlortetracycline hydrochloride in a drench or drinking water as follows:  <!-- PJG 0012 frnewline --> (i) <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 -->  Calves <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . (A)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Amount <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . Ten milligrams per pound of body weight daily in divided doses.  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> (1) <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  Control and treatment of bacterial enteritis (scours) caused by  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> E. <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->   <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> coli <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  and bacterial pneumonia (shipping fever) associated with  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Pasteurella <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  spp.,  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> A. <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->   <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> pleuropneumoniae <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  ( <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Hemophilus <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  spp.), and  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Klebsiella <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  spp.  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> (2) <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->   <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Limitations <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . Prepare fresh solution daily; as sole source of chlortetracycline; administer for not more than 5 days; do not slaughter animals for food within 24 hours of treatment; do not administer this product with milk or milk replacers; administer 1 hour before or 2 hours after feeding milk or milk replacers; a withdrawal period has not been established in preruminating calves; do not use in calves to be processed for veal.  <!-- PJG 0012 frnewline --> (B) [Reserved]  <!-- PJG 0012 frnewline --> (ii) [Reserved]  <!-- PJG 0012 frnewline --> (3) [Reserved]  <!-- PJG 0012 frnewline --> (4) *&blank;*&blank;*  <!-- PJG 0012 frnewline --> (i) *&blank;*&blank;*  <!-- PJG 0012 frnewline --> (C)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Amount <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . One thousand milligrams per gallon.  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> (1) Indications for use <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . Control of mortality due to fowl cholera caused by  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Pasteurella multocida <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  susceptible to chlortetracycline.  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> (2) Limitations <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . See paragraph (d)(4)(i)(A)( <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> 2 <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> ) of this section.  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=37 g=1 f=1 --> * * * * *  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> (iii) *&blank;*&blank;*  <!-- PJG 0012 frnewline --> (B)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Indications for use <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . Control and treatment of bacterial enteritis (scours) caused by  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> E <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> .  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> coli <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  and  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Salmonella <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  spp. and bacterial pneumonia associated with  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Pasteurella <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  spp.,  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Actinobacillus pleuropneumoniae <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  ( <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Hemophilus <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  spp.), and  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Klebsiella <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  spp.  <!-- PJG 0012 frnewline --> (C)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Limitations <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . Prepare fresh solution daily; as sole source of chlortetracycline; do not use for more than 5 days; for 017274, 053389, and 054273 do not slaughter animals for food within 5 days of treatment; for 010042 do not slaughter animals for food within 24 hours of treatment.  <!-- PJG 0012 frnewline --> (iv) *&blank;*&blank;*  <!-- PJG 0012 frnewline --> (B)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Indications for use <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . Control and treatment of bacterial enteritis (scours) caused by  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> E <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> .  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> coli <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  and  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Salmonella <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  spp. and bacterial pneumonia (shipping fever complex) associated with  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Pasteurella <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  spp.,  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> A. pleuropneumoniae <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  ( <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Hemophilus <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  spp.), and  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Klebsiella <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  spp.  <!-- PJG 0012 frnewline --> (C)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Limitations <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> . Prepare fresh solution daily; use as a drench; as sole source of chlortetracycline; do not use for more than 5 days; do not slaughter animals for food within 24 hours of treatment; do not use in lactating cattle; do not administer this product with milk or milk replacers; administer 1 hour before or 2 hours after feeding milk or milk replacers; a withdrawal period has not been established in preruminating calves; do not use in calves to be processed for veal.  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG QTAG 04 --> <!-- PJG /QTAG -->   <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=21 g=1 f=1 --> Dated: July 27, 1994.  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </SUPPLEM> <SIGNER> <!-- PJG ITAG l=06 g=1 f=1 --> Robert C. Livingston,  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </SIGNER> <SIGNJOB> <!-- PJG ITAG l=04 g=1 f=1 --> Director, Office of New Animal Drug Evaluation, Center for Veterinary Medicine.  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </SIGNJOB> <FRFILING> <!-- PJG ITAG l=40 g=1 f=1 --> [FR Doc. 94&hyph;18926 Filed 8&hyph;2&hyph;94; 8:45 am]  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </FRFILING> <BILLING> <!-- PJG ITAG l=68 g=1 f=1 --> BILLING CODE 4160&hyph;01&hyph;F <!-- PJG /ITAG --> </BILLING>  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /STAG --></p>
		</main>
</body></html>
            